Related Experiment Video
Updated: Sep 9, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non-Small Cell Lung Cancer
Cheng Pei Wu1, Aria Vaishnavi1,2
1Department of Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Lung adenocarcinoma has become a paradigm for precision oncology and success with targeted therapies. However, large chunks of the pie chart of molecular drivers remain unknown, preventing many patients from similarly benefiting from this strategy. Here, we highlight the side-by-side release of two impactful studies from Mozzarelli and colleagues and DiMarco and colleagues in this issue of Cancer Research. Here, each team generated unique mouse models characterizing a novel and potentially actionable driver and facilitator of acquired drug resistance in lung adenocarcinoma, RIT1M90I. Both study teams describe and characterize their new mouse models, reporting the tumor latency and importantly revealing the sensitivity of RIT1-mutant lung tumors to SHP2 or RAS tricomplex inhibitors. Collectively, these findings highlight the importance of RIT1M90I as an actionable driver of lung adenocarcinoma and a potent mediator of acquired drug resistance. These new RIT1-driven lung cancer models represent valuable tools for the preclinical testing and translation of different therapeutic strategies for this patient population. See related article by Mozzarelli et al., p. 3196 See related article by DiMarco et al., p. 3207.
Insights
Two new studies reveal RIT1M90I as a key driver in lung adenocarcinoma, promoting drug resistance. Mouse models show RIT1-mutant tumors respond to SHP2 or RAS inhibitors, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung adenocarcinoma is a model for precision oncology but unknown molecular drivers limit targeted therapy success.
- Acquired drug resistance remains a significant challenge in treating lung adenocarcinoma.
Purpose of the Study:
- To characterize RIT1M90I as a novel driver and facilitator of acquired drug resistance in lung adenocarcinoma.
- To introduce and validate new mouse models for studying RIT1-driven lung cancer.
Main Methods:
- Generation and characterization of unique mouse models for RIT1M90I.
- Assessment of tumor latency and drug sensitivity in RIT1-mutant lung tumors.
- Evaluation of response to SHP2 and RAS tricomplex inhibitors.
Main Results:
- RIT1M90I was identified as a novel actionable driver in lung adenocarcinoma.
- The generated mouse models exhibit sensitivity to SHP2 or RAS tricomplex inhibitors.
- RIT1-mutant lung tumors demonstrated sensitivity to targeted inhibitors.
Conclusions:
- RIT1M90I is an important driver of lung adenocarcinoma and a mediator of acquired drug resistance.
- New RIT1-driven lung cancer models are valuable for preclinical testing of therapeutic strategies.
- Targeting RIT1 mutations offers a promising approach for overcoming drug resistance in lung adenocarcinoma.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...